44 results about "Malignant Glomus Tumor" patented technology

A method and kit is provided to quantifying and qualifying exosomes in human cell derived samples or in body fluid based on expression of TM9-superfamily proteins on the exosomes. Furthermore, a method and a kit to diagnose malignant tumors is provided. The disclosure also provides a method to monitor tumor growth.

The invention provides a method of manufacturing an oligonucleotide gene chip for screening and diagnosing the normally gynecological malignant tumor in early phase and the method of detecting the same. The method uses the related genes of normally gynecological malignant tumor (breast cancer, ovarian cancer and uterine cancer) as control, and determines whether the patient has the malignant tumor by manufacturing the oligonucleotide and chip hybridizing and detecting. The invention provides a detecting method of screening and diagnosing the normally gynecological malignant tumor in early phase based on gene chip, which makes the characteristic gene of the normally gynecological malignant tumor into a gene chip so as to keep the consistence of the clinic detecting condition. The method can screen and diagnose the normally malignant tumor ASAP. With convenience in sampling and good consistence, the method of the invention is prone to popularize; by proper application, the cancer mortality can be reduced by 1/3.

The invention relates to a therapeutic vaccine for malignant tumors and a composition thereof. The therapeutic vaccine for malignant tumors is a tumor cell line which contains plasmid of antisense nucleic acid of human transforming growth factor beta (TGF-beta2); the therapeutic vaccine composition for malignant tumors comprises the therapeutic vaccine for malignant tumors and an immunopotentiator, and the immunopotentiator is one selected from the group consisting of a Corynebacterium parvum preparation, a non-cell Corynebacterium parvum preparation, a BCG polysaccharide, a nucleic acid preparation, a Nocardia rubra-cell wall skeleton preparation, a group A Streptococcus preparation, a non-cell group A Streptococcus preparation, a Pseudomonas aeruginosa preparation, a non-cell Pseudomonas aeruginosa preparation, a Brucella preparation, a non-cell Brucella preparation, a non-cell Mycobacterium vaccae preparation and a non-cell Mycobacterium smegmatis preparation, preferably the non-cell Corynebacterium parvum preparation; and the malignant tumors include a lung cancer, a liver cancer, a pancreatic cancer, leukemia, lymphoma, an ovarian cancer, a colon cancer, a stomach cancer and a breast cancer.

The invention discloses a microsphere-gel slow-release preparation for treating malignant tumor and thoracic-celiac metastasis. The preparation comprises a microsphere base, antitumor drug and a gel carrier for dispersing the microsphere base and the antitumor drug, the antitumor active drug is loaded on the microsphere base, loading amount of the antitumor active drug on the microsphere base is 1-50%, and a mass ratio of the microsphere base to the gel carrier is 1:3-5. The microsphere base can be segmented copolymer or homopolymer, and when the microsphere base is the segment copolymer, number-average molecular weight ratio of a hydrophobic chain segment to a hydrophilic chain segment is 1-2500. The microsphere-gel slow-release preparation which is chemotherapy drug is formed by loadingchemotherapy drug on high molecular polymer, and the preparation can generate slow-release and antitumor effects when being in-situ injected into a body; the preparation has relatively little whole-body toxic and side effect, so that better continuous treatment effect is realized.

The invention discloses a polyethylene glycol-gambogic acid liposome, which is composed of a polyethylene glycol-gambogic acid conjugate, polyethylene glycol, vitamin E, cholesterol and phospholipid in a weight ratio of 1-10:0.5-2:0.05-0.2:1-4:10-30. According to the invention, an amphiphilic polymer PEG and an antitumor drug gambogic acid are connected with an ester bond into a conjugate amphipathic PEG-GA, and the PEG-GA is inserted into a liposome bimolecular layer to construct a nano targeted drug delivery system, the water solubility of the drug can be improved, also the drug stability and antitumor effect can be enhanced, drug accumulation in normal tissue can be reduced, the survival time of tumor-bearing mice is prolonged, the treatment efficacy is improved and the toxic and side effects are reduced. The invention also provides a preparation method and application of the liposome, and the liposome can be applied to treatment of lung cancer, ovarian cancer, breast cancer, colorectal cancer, melanoma, head and neck cancer, lymphoma or brain tumors.

The invention discloses a method used for differentiating benign tumor (pulmonary sclerosing pneumocytoma) and malignant tumor (adenocarcinoma in situ) based on infrared light spectrums. The method comprises following steps: benign tumor and malignant tumor tissue slices are collected, slice infrared transmitted spectrums are collected at 4000 to 1900cm<-1> range at a resolution ratio of 8cm<-1> and scanning time of 64; the obtained spectrums are not subjected to pretreatment, or are subjected to SGS pretreatment, mole construction spectrum range upper limit is determined to be 4000 to 3960cm<-1>, the lower limit is determined to be 1960cm<-1>, the former 4 to 9 main ingredients are selected, discriminant analysis method or counter propagation network are adopted to construct a model usedfor differentiating benign tumor and malignant tumor; a property unknown tumor tissue slice is selected, and spectrum data processing is carried out through the above steps, and at last the constructed model is adopted for prediction. The method can be used for accurate, objective, rapid, and economical differentiating of benign tumor and malignant tumor.

The invention provides an application of reagents for detecting biomarkers in bile in preparation of a tool for diagnosing liver cancer, malignant biliary tract tumors or pancreatic cancer. The invention also provides a tool for diagnosing liver cancer, malignant biliary tract tumors or pancreatic cancer, wherein the tool comprises a reagent for detecting the biomarkers in the bile. The method andtool provided by the invention take the bile as a detection object, has a sample easy to obtain without any adverse effects, and can effectively obtain relevant information involving tumors such as liver cancer, malignant biliary tract tumors or pancreatic cancer.

The invention discloses a reproducible kidney cancer therapeutic DNA vaccine. The reproducible kidney cancer therapeutic DNA vaccine is obtained by inserting a compound gene sig-tG250-Fc-GPI-IRES-GM/B7 into a reproducible DNA vaccine carrier pSVK. The reproducible kidney cancer therapeutic DNA vaccine is a DNA vaccine capable of inducing self anti-tumor immune response, has good safety and broad application prospect and provides a new method and thinking for prevention and treatment of malignant tumors.

The invention provides an application of morusin or its pharmaceutically acceptable derivative in preparation of medicines for resisting malignant tumor. The invention also provides an application of morusin or its pharmaceutically acceptable salt in preparation of anti-glioma medicines. It is found through researches that morusin shows a good activity of resisting malignant tumor (such as glioma) in vitro and in vivo. In addition, it shows through experiments that morusin has a good effect of suppressing tumor growth and inducing transversal differentiation and apoptosis of tumor cells and tumor stem cells, and has little toxic and side effect on normal cells. The morusin has a good application prospect.

The present invention discloses proteasome inhibitors of tripeptide boronic acids or boronic esters represented by Formula (I), preparative method and use thereof. The proteasome inhibitors are therapeutical agents for treating malignant tumor, various nervous system degenerative diseases, muscle cachexia or diabetes, wherein the malignant tumor is leukemia, gastric cancer, hepatocarcinoma or nasopharyngeal carcinoma.

The present invention relates to a medicine made up by using the Chinese medicinal materials of black nightshade, polyporus, zedoary, ligustrum fruit, vaccaria seed and psoralea seed as main component for curing malignant tumors of prostatic carcinoma, liver cancer and sarcoma, specially for curing prostatic carcinoma. Besides, in said invented medicine one of the Chinese medicinal materials of astragalus root, flowery knotweed root, poria, prunella spike and pangolin scles, etc. or their combination can be added.

The invention relates to compounds capable of serving as tyrosine kinase inhibitors and medicinal application thereof in treating malignant tumor. Compared with the prior art, the oxidative metabolism of the compounds provided by the invention is reduced, and the medicinal power performance is improved; and moreover, the compounds have the advantages of less dosage and small side effects.

The invention discloses a combined drug for immunotherapy of malignant tumors. The combined drug includes a preparation containing interleukin 2, and a preparation containing intestinal probiotics; the pharmacological studies confirm that the combined drug of the present invention has a function of reducing tumor burden and controlling tumor growth, can promote the infiltration of cytotoxic T cells and the differentiation and differentiation of dendritic cells, improve the tumor immune microenvironment, can make up for the deficiency of the interleukin 2 alone in the tumor immune microenvironment, and can be applied to the immunotherapy of various malignant tumors.

I study Neijing and Compendium of Materia Medica for many years, screen out natural medicinal materials which grow in China, and develop a special-acting drug-a traditional Chinese medicine anticanceragent which can resist malignant tumors in the middle and advanced stages. The agent is non-toxic, and has special effects on lung, stomach, liver, kidney, heart disease, esophagus, breast, thyroid,cervix, colorectal, leukemia and the like, and cure rate is much higher than 62%. For the human immunodeficiency virus, the agent can reduce a HIV viral load. The mechanism of the agent is to block anenergy source of cancer cells, resist the growth of tumor angiogenesis, enhance immune functions, (devour and destroy heterogeneity in blood), induce tumor cell apoptosis and block oncogene mutationand transcription. If the traditional Chinese medicine anticancer agent is taken, pain, nausea and vomiting are soon alleviated and disappeared. Diet is increased, sleep is improved, physical strengthis increased, and the development of the cancer cells is obviously controlled. A tumor block is softened, shrunk and disappeared. After two to three courses of treatment (three months after one course of the treatment), B-ultrasound or CT are used for re-examination of a patent with fast curative effect, a primary lesion disappears, no metastasis and recurrence occurs, and the patient has good health.

The invention relates to itraconazole applied to treatment of gastric cancer, lung cancer and liver cancer, and a composition of the itraconazole. The daily dose of the itraconazole is 0.1-5000mg, and the itraconazole has good curative effect when the daily dose is 200mg. The itraconazole and the composition of the itraconazole disclosed by the invention have the beneficial effects that by subcutaneous injection of the itraconazole solution or the composition, the survival time of high and low-dose groups of SPF-grade Konmin mice that have liver cancer H22 can be prolonged. The itraconazole or the composition of the itraconazole has obvious inbibitional effect on Lewis lung cancer of mice in comparison with the control group according to the influence on subcutaneous tumor of the Lewis lung caner, the growth rate (P(0.01) of the tumor can be slowed down; the size (P(0.01) of the tumor is reduced; and the tumor control rate is respectively 43.0% and 45.6% after the treatment is ended. The itraconazole or the composition of the itraconazole influences positive staining of the human gastric cancer tissue VEGF (Vascular Endothelial Growth Factor) in cell cytoplasm, and the VEGF positive expression of a 0.9% sodium chloride solution group is obviously higher than that of the itraconazole group (P(0.05).

The present invention relates to an SENP1 protein inhibitor and a use thereof, in particular, the invention relates to an SENP1 protein inhibitor shRNA, a use of the SENP1 protein inhibitor in preparation of drugs for preventing or treating malignant blood tumor, and a use in preparation of drugs for inhibiting the proliferation of malignant blood tumor cells and/or promoting the apoptosis of the malignant blood tumor cells. The invention further relates to a method for screening the drugs for preventing or treating malignant blood tumor.

The invention discloses a method for treating malignant tumors by using nickase, belonging to the field of medical technology. According to the invention, malignant tumor cells are treated so as to allow malignant tumor cell tissue to resemble an early-stage malignant tumor; an envelope is formed out of the malignant tumor cell resembling the early-stage malignant tumor, and excision is carried out; and after excision, a tumor sample acquired from the early-stage malignant tumor is subjected to acquisition of malignant tumor cells for sequencing, followed-up calculation and positioning of the recognition sequence of endonuclease so as to complete designing of endonuclease; and the endonuclease enters a body via an in-vivo delivery tool such as a deactivated virus and cleaves malignant tumor promoter at a certain site and sequences at other sites. The method provided by the invention poses no harm to normal cells while killing cancer cells, has little side effect and can realize fixed-point elimination.

The invention discloses soup with the effects of strengthening the body resistance and eliminating diseases for treating malignant tumors and application of the soup. The soup is prepared from 30-150parts of hairyvein agrimony, 20-60 parts of nightshade, 30-100 parts of raw milkvetch roots, 5-15 parts of rhizoma curcumae, 6-30 parts of honeycombs, 5-30 parts of stiff silkworms, 6-20 parts of geckos, 15-60 parts of bittersweet, 10-60 parts of barbed skullcap herb, 3-10 parts of raw liquorice roots and 30-150 parts of oldenlandia diffusa. The soup has the effects of tonifying qi and strengthening the body resistance, activating blood to remove blood stasis, and removing toxins and eliminating stasis, and can effectively treat multiple malignant tumors.

The invention belongs to the biopharmaceutical field, and particularly relates to a digestive system malignant tumor marker, and a method for preparing drugs for restraining digestive system malignanttumors. HYAL2 is used for clinical diagnosis of the digestive system malignant tumors, luminescence quantification PCR is used for detecting the expression situation in the digestive system malignanttumors, and according to the expression situation, HYAL2 is used as a molecule maker for the early diagnosis of the digestive system malignant tumors. A carrier for interference HYAL2 gene expressionis constructed for the drugs for restraining the digestive system malignant tumors. The constructed carrier is used for preparing the drugs for in vitro application or in vivo application. Massive experiment data proves that the HYAL2 exerts important adjusting and controlling effects in the generation and development process of the digestive system malignant tumors, the interference HYAL2 gene expression can notably restrain the proliferation and the migration of digestive system malignant tumor cells, and the HYAL2 is hopeful to prepare a new drug for preventing and treating the digestive system malignant tumors.